ML171
Based on 18 publication(s) in Google Scholar
ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 6631-94-3
- Formula: C14H11NOS
- Molecular Weight:241.31
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Ferroptosis Compound Library
HY-L051
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) ML171
More- Redox Biol. 2020 Jul;34:101569. [Abstract]
- Int J Biol Macromol. 2021 Sep 30:187:513-527. [Abstract]
- Redox Rep. 2025 Dec;30(1):2494314. [Abstract]
- Antioxid Redox Signal. 2024 Sep;41(7-9):488-504. [Abstract]
- Cell Biol Toxicol. 2023 Oct;39(5):2207-2225. [Abstract]
- J Ginseng Res. 2025 Jul;49(4):426-437. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116242. [Abstract]
- Biochem Pharmacol. 2023 Dec:218:115934. [Abstract]
- Biochem Pharmacol. 2023 Sep:215:115738. [Abstract]
- Biochem Pharmacol. 2023 May:211:115494. [Abstract]
- Biochem Pharmacol. 2023 Mar:209:115442. [Abstract]
- Cells. 2021 Aug 12;10(8):2073. [Abstract]
- Inflammation. 2023 Jun;46(3):1002-1021. [Abstract]
- Pharmaceuticals (Basel). 2022 Aug 27;15(9):1066. [Abstract]
- J Hypertens. 2024 Apr 23. [Abstract]
- J Cell Physiol. 2021 Nov;236(11):7356-7375. [Abstract]
- Toxicol Appl Pharmacol. 2023 Sep 1:474:116625. [Abstract]
- Toxicol Appl Pharmacol. 2022 Jan 15:435:115847. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
|
NOX1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-1080 | EC50 |
0.038 μM
Compound: P22
|
Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 33065375] |
Nox1-dependent ROS generation has been shown to play a pivotal role in cell signaling, cell growth, angiogenesis, motility and blood pressure regulation. ML171 strongly blocks ROS generation in HT29 cells (IC50=0.129 μM) and only increasing over-expression of Nox1 can overcome the blockage of ROS generation caused by ML171 treatment in HEK293 cell system reconstituted with all the components required Nox1-dependent ROS generation. ML171 efficiently blocks ROS production measured by carboxy-H2-DCFDA staining as well as DPI used as a positive control. When ML171 is tested in HEK293-Nox1 reconstituted cell system, higher potency in blocking Nox1-dependent ROS generation is observed compared with the parental compound[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 6631-94-3
-
Appearance Solid
-
Molecular Weight 241.31
-
Formula C14H11NOS
-
Color Yellow to orange
-
SMILES
CC(C1=CC=C2SC3=CC=CC=C3NC2=C1)=O
-
Synonyms
2-Acetylphenothiazine; 2-APT
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
p47phox deficiency impairs platelet function and protects mice against arterial and venous thrombosis. [Abstract]2020 Jul;34:101569. PMID: 32422541 -
Int J Biol Macromol
Carboxyl group-modified α-lactalbumin induces TNF-α-mediated apoptosis in leukemia and breast cancer cells through the NOX4/p38 MAPK/PP2A axis. [Abstract]2021 Sep 30:187:513-527. PMID: 34310992 -
Redox Rep
Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation. [Abstract]2025 Dec;30(1):2494314. PMID: 40269356 -
Antioxid Redox Signal
Intervention of asprosin attenuates oxidative stress and neointima formation in vascular injury. [Abstract]2024 Sep;41(7-9):488-504. PMID: 38814824 -
Cell Biol Toxicol
Effects of SIDT2 on the miR-25/NOX4/HuR axis and SIRT3 mRNA stability lead to ROS-mediated TNF-α expression in hydroquinone-treated leukemia cells. [Abstract]2023 Oct;39(5):2207-2225. PMID: 35302183 -
J Ginseng Res
Ginsenoside Rg5 modulates the TLR4 and BCL-2 pathways by inhibiting NOX1, thereby alleviating inflammation, apoptosis and pyroptosis in hyperuricemia nephropathy. [Abstract]2025 Jul;49(4):426-437. PMID: 40621077 -
Biochem Pharmacol
ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. [Abstract]2024 Jun:224:116242. PMID: 38679209 -
Biochem Pharmacol
Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition. [Abstract]2023 Dec:218:115934. PMID: 37989415 -
Biochem Pharmacol
BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells. [Abstract]2023 Sep:215:115738. PMID: 37562509 -
Biochem Pharmacol
Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. [Abstract]2023 May:211:115494. PMID: 36924905 -
Biochem Pharmacol
AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells. [Abstract]2023 Mar:209:115442. PMID: 36720359 -
Cells
2021 Aug 12;10(8):2073. PMID: 34440842 -
Inflammation
BRD9 Inhibition Attenuates Matrix Degradation and Pyroptosis in Nucleus Pulposus by Modulating the NOX1/ROS/NF-κB axis. [Abstract]2023 Jun;46(3):1002-1021. PMID: 36801999
ML171 purchased from MedChemExpress. Usage Cited in: Inflammation. 2023 Jun;46(3):1002-1021. [Abstract]
In rat NP cells, ML171 inhibits the expression of catabolic markers MMP13, ADAMTS4, ADAMTS5, and pyroptotic markers NLRP3, GSDMD-NT, and cleaved-caspase-1, as well as incresaes the expression of ECM anabolic markers COL2A and ACAN, by inhibiting overexpression of BRD9 (Fig. c and d).
-
Pharmaceuticals (Basel)
2022 Aug 27;15(9):1066. PMID: 36145287 -
J Hypertens
Asprosin contributes to vascular remodeling in hypertensive rats via superoxide signaling. [Abstract]2024 Apr 23. PMID: 38690935 -
J Cell Physiol
NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. [Abstract]2021 Nov;236(11):7356-7375. PMID: 33982799 -
Toxicol Appl Pharmacol
Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. [Abstract]2023 Sep 1:474:116625. PMID: 37451322 -
Toxicol Appl Pharmacol
CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. [Abstract]2022 Jan 15:435:115847. PMID: 34963561
Solvent & Solubility
DMSO : ≥ 64 mg/mL (265.22 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
HT29 cells are cultured in 150 mm diameter plate and when 70-80% confluence is reached, cells are trypsinized, harvested in HBSS and counted. 4×104 cells are dispensed into individual wells in 30 μL final volume (384 well plates) by using a robotic liquid handler. Cells are treated for 60 min at 37°C with 50 nL of DPI, DMSO and library compounds (including ML171) which are automatically dispensed into individual wells from their respective assay plates. This will correspond to a final concentration of 10 μM DPI or library compounds (ML171), and 0.1% DMSO. 20 μL of a mixture containing 200 μM luminol plus 0.32 units of HRP (final concentration) is added. Luminescence is quantified using a 384-well plate luminometer. The data output consisting of the emission intensities for each well is imported into a spread-sheet program (such as Excel) for further processing. As designed, compounds that inhibit Nox1 activity will reduce cellular ROS production, leading to reduced probe-ROS interactions and reduced well luminescence. Compounds are considered ‘hits’ and further processed when light emission is blocked >75% 7 than DMSO wells (DMSO and DPI wells are set to 0% and 100% respectively). Compounds are tested in singlicate at a concentration of 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1440 mL | 20.7202 mL | 41.4405 mL | 103.6012 mL |
| 5 mM | 0.8288 mL | 4.1440 mL | 8.2881 mL | 20.7202 mL | |
| 10 mM | 0.4144 mL | 2.0720 mL | 4.1440 mL | 10.3601 mL | |
| 15 mM | 0.2763 mL | 1.3813 mL | 2.7627 mL | 6.9067 mL | |
| 20 mM | 0.2072 mL | 1.0360 mL | 2.0720 mL | 5.1801 mL | |
| 25 mM | 0.1658 mL | 0.8288 mL | 1.6576 mL | 4.1440 mL | |
| 30 mM | 0.1381 mL | 0.6907 mL | 1.3813 mL | 3.4534 mL | |
| 40 mM | 0.1036 mL | 0.5180 mL | 1.0360 mL | 2.5900 mL | |
| 50 mM | 0.0829 mL | 0.4144 mL | 0.8288 mL | 2.0720 mL | |
| 60 mM | 0.0691 mL | 0.3453 mL | 0.6907 mL | 1.7267 mL | |
| 80 mM | 0.0518 mL | 0.2590 mL | 0.5180 mL | 1.2950 mL | |
| 100 mM | 0.0414 mL | 0.2072 mL | 0.4144 mL | 1.0360 mL |
Powered by Bioz